Esketamine Nasal Spray for Rapid Reduction of Depressive Symptoms in Patients With Major Depressive Disorder Who Have Active Suicide Ideation With Intent: Results of a Phase 3, Double-Blind, Randomized Study (ASPIRE II)

BACKGROUND: Patients with major depressive disorder (MDD) having active suicidal ideation with intent require immediate treatment. METHODS: This double-blind study (ASPIRE II) randomized adults (aged 18–64 years) with MDD having active suicidal ideation with intent to esketamine 84 mg or placebo nas...

Descripción completa

Detalles Bibliográficos
Autores principales: Ionescu, Dawn F, Fu, Dong-Jing, Qiu, Xin, Lane, Rosanne, Lim, Pilar, Kasper, Siegfried, Hough, David, Drevets, Wayne C, Manji, Husseini, Canuso, Carla M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Regular Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7816667/
https://www.ncbi.nlm.nih.gov/pubmed/32861217
http://dx.doi.org/10.1093/ijnp/pyaa068

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7816667/
https://www.ncbi.nlm.nih.gov/pubmed/32861217
http://dx.doi.org/10.1093/ijnp/pyaa068

Ejemplares similares